Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-25
2006-07-25
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S300000, C514S301000, C514S303000, C514S373000, C514S397000, C514S411000, C514S421000
Reexamination Certificate
active
07081464
ABSTRACT:
Novel amides and imides are inhibitors of tumor necrosis factorα and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions.
REFERENCES:
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5712291 (1998-01-01), D'Amato
patent: 5728844 (1998-03-01), Muller et al.
patent: 5728845 (1998-03-01), Muller et al.
patent: 5798368 (1998-08-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 5968945 (1999-10-01), Muller et al.
patent: 6011050 (2000-01-01), Muller et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6114355 (2000-09-01), D'Amato
patent: 6180644 (2001-01-01), Muller et al.
patent: 6214857 (2001-04-01), Muller et al.
patent: 6228879 (2001-05-01), Green et al.
patent: 6235756 (2001-05-01), D'Amato
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6380239 (2002-04-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6476052 (2002-11-01), Muller et al.
patent: 6518281 (2003-02-01), Muller et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6656964 (2003-12-01), Muller et al.
patent: 6667316 (2003-12-01), Man
patent: 6673828 (2004-01-01), Green et al.
patent: 6699899 (2004-03-01), Man et al.
patent: 2002/0173658 (2002-11-01), Muller et al.
patent: 2003/0139451 (2003-07-01), Shah et al.
patent: 2004/0147558 (2004-07-01), Treston et al.
patent: WO 94/20085 (1994-09-01), None
patent: WO 98/19649 (1998-05-01), None
patent: WO 02/064083 (2002-08-01), None
patent: WO 02/070480 (2002-09-01), None
Al-Soud and Al-Masoudi, “Synthesis and antitumor activity of some phthalimide analogues,”Pharmazie 56: 372-375 (2001).
Bauer et al., “Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent,”Biochem Pharmacol 55: 1827-1834 (1998).
Boylen et al., “Teratogenic Effects of Thalidomide and Its Metabolites on the Developing Chick Embryo,”Canadian J. of Biochem. 42: 35-42 (1964).
Buelens, “Treatment of a grade II astrocytoma with thalidomide,”Arzneimittel-Forschung 17: 646-648 (1967).
Cavala and Frith, “Phosphodiesterase Type IV Inhibitors: Structural Diversity and Therapeutic Potential In Asthma,”Current Medicinal Chemistry 2: 561-572 (1995).
Colville-Nash and Scott, “Angiogenesis and Rheumatoid Arthritis: Pathogenic and Therapeutic Implications,”Ann. Rheum. Dis. 51: 919-25 (1992).
Craig et al., “Potential anticancer agents. III. 2-phthalimidoaldehydes and derivatives,”Potential Anticancer Agents. III 10:1071-1073 (1967).
D'Amato et al., “Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma,”Semin. Oncol. 28:597-601 (2001).
D'Amato et al., “Thalidomide is an Inhibitor of Angiogenesis,”Proc. Natl. Acad. Sci. 91:4082-4085 (1994).
De and Pal, “Hansch analysis for some antineoplastic glutarimides,”J. Indian Chem. Soc. LIII: 825-826 (1976).
De and Pal, “Possible antineoplastic agents I,”J. Pharm. Sci. 64: 262-266 (1975).
De and Pal, “Possible antineoplastic agents II,”J. Pharm. Sci. 66: 232-235 (1977).
De and Ghose., “Possible antineoplastic agents: III. Synthesis of 6-alkyl-2-[4′-methoxphthalimido] and 6-alkyl-3-[3′-4′-dimethoxyphenyl] glutarimides,”J. Indian Chem. Soc. LIII: 1122-1125 (1976).
De and Ghose, “Possible antineoplastic agents: part IV—synthesis & antineoplastic potency of N-substituted α-(4,5-dimethoxyphthalimido)glutarimides & β-(4-bromophenyl)glutarimides,”Indian Jour. Chem. 16B: 510-512 (1978).
De and Pal., “Quantitative structure-activity relationship (QSAR) and rational drug design for some antineoplastic thalidomide and glutarimide derivatives,”J. Indian Chem. Soc. LIII: 1049-1052 (1976).
DiPaolo, “In vitro test systems for cancer chemotherapy, II, correlation of in vitro inhibition of dehydrogenase and growth with in vivo inhibition of Ehrlich ascites tumor,”P.S.E.B.M. 140: 384-387 (1963).
Fabro et al., “Teratogenic Activity of Thalidomide and Related Compounds,”Life Sciences 3: 987-92 (1964).
Folkman and Shing, “Angiogenesis,”J. Biol. Chem. 267: 10931-4 (1992).
Gelato et al., “Inhibition of prolactin release by a thalidomide-related compound,”P.S.E.B.M. 114: 167-168 (1972).
Gershbein, “The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas,”Cancer Lett. 60: 129-133 (1991).
Grabstald and Golbey, “Clinical experiences with thalidomide in patients with cancer,”Clinical Pharmacology and Therapeutics 6: 298-302 (1965).
Jönsson, “Chemical Structure and Teratogenic Properties,”Acta Pharma. Suecica 9: 521-542 (1972).
Koch, “The Arene Oxide Hypothesis of Thalidomide Action: Consideration s on the Molecular Mechanism of Action of the ‘Classical’ Teratogen,”Sci. Pharm. 49: 67-99 (1981).
Koch, “The Arene Oxide Hypothesis of Thalidomide Action: Consideration s on the Molecular Mechanism of Action of the ‘Classical’Teratogen,”Sci. Pharm. 49: 67-99 (1981) (English-language abstract).
Koch, “Thalidomide and Cogeners as Anti-inflammatory Agents,”Progress in Medicinal Chemistry 22: 166-242 (1985).
Lentzsch et al., “S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice,”Cancer Research62:2300-2305 (2002).
Lombardo, L.J., “Phospodiesterase-IV Inhibitors: Novel Therapeutics for the Treatment of Inflammatory Diseases,”Current Pharmaceutical Design I:255-269 (1995).
Lowe, J.A. and Cheng, J.B., “The PDE IV Family of Calcium-independent Phosphodiesterase Enzymes,”Drugs of the Future 17: 799-807 (1992).
Luzzio et al., “Synthesis and antiangiogenic activity of 2-deoxygenated analogs and 6′-deoxygenated metabolic analogs of thalidomide,”Abstracts of Papers-American Chemical Society 223: Abstract No. 185 (2002).
Menard et al., “Quelques Metabolites Possibles de la Thalidomide,”Canadian J. Chem. 41: 1722-5 (1963).
Miyachi et al., “Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity,”J. Med. Chem. 40: 2858-2865 (1997).
Mückter, “Thalidomide and tumor,”Antimicrobial Agents and Chemotherapy: 531-538 (1965).
Olson et al., “Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer,”Clinical Pharmacology and Therapeutics 6: 292-297 (1965).
Palfreyman, “Phosphodiesterase Type IV Inhibitors As Inti-inflammatory Agents,”Drugs of the Future 20: 793-804 (1995).
Suaer et al., “Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals,”Am. J. Pathol. 156: 151-158 (2000).
Schumacher et al., “The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species,”Brit. J. Pharmacol. 25: 338-351 (1965).
Schweigerer and Fotsis, “Angiogenesis and Angiogenesis Inhibitors in Pediatric Diseases,”Eur. J. Pediatr. 151: 472-476 (1992).
Sekut and Connolly, “Pathophysiology and Regulation of TNF-α in Inflammation,”DN&P 9: 261-269 (1996).
Shah et al., “Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis,”J. Med. Chem. 42: 3014-3017 (1999).
Shibata et al., “N-alkylphthalimides: structural requirement of thalidomidal action on 12-0-tetrad
Muller George W.
Shire Mary
Celgene Corporation
Jones Day
Kifle Bruck
LandOfFree
Topical compositions of cyclic amides as immunotherapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical compositions of cyclic amides as immunotherapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical compositions of cyclic amides as immunotherapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3538389